CDC ENTEBBE

pH-D Feminine Health has launched the first FDA-cleared Phase 3 clinical trial to validate boric acid suppositories as a treatment for yeast infections, marking a critical milestone in women's health research.

Vaccine maker Bavarian Nordic has agreed in principle to a roughly $3 billion take-private offer from private equity firms Nordic Capital and Permira, with completion expected in the fourth quarter.

A federal judge has halted the Trump administration's mass layoffs at the Department of Health and Human Services, ruling the cuts likely violated federal law and caused irreparable harm.

A comprehensive CDC VISION Network study spanning over 345,000 emergency department encounters and 111,000 hospitalizations found that 2023-2024 COVID-19 vaccines reduced critical illness risk by 48% during the first seven to 299 days after vaccination.

Rutgers Health researchers found lamotrigine safe in older adults with epilepsy, contradicting a 2020 FDA safety warning about potential heart risks.

The Trump administration has terminated funding for multiple HIV vaccine research programs, including major efforts at Duke Human Vaccine Institute and Scripps Research Institute that have been running since 2012.

The MAHA Commission has outlined an enhanced research framework focused on drug safety in pediatric populations, addressing critical gaps in current safety monitoring systems.

Soligenix is developing SGX943 (dusquetide), a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics.

The FDA has announced major changes to COVID-19 vaccine approvals, requiring placebo-controlled clinical trials for shots intended for healthy adults and children, effectively ending routine annual approvals for these groups.

University of Illinois Chicago researchers have developed a novel antibiotic that could make it 100 million times harder for bacteria to develop resistance, potentially revolutionizing treatment of drug-resistant infections.